Posted On: 02/19/2014 11:56:08 AM
Post# of 144774
$MRK Recent News
Updates, advisories and surprises 6:01 p.m. Feb. 5, 2014 - MarketWatch
U.S. stocks fall; data stoke fears of slowdown 4:31 p.m. Feb. 5, 2014 - Anora Mahmudova
Stocks dip, end off day's lows; Twitter falls after hours: stock market live blog recap 4:27 p.m. Feb. 5, 2014 - blogs.marketwatch.com
3D Systems down on weak outlook, CVS quits cigarettes 4:16 p.m. Feb. 5, 2014 - Saumya Vaishampayan
The big Merck news centers on cancer-drug collaborations with other giants 11:02 a.m. Feb. 5, 2014 - blogs.marketwatch.com
U.S. stock futures turn up before market open 9:21 a.m. Feb. 5, 2014 - Barbara Kollmeyer
Twitter, the Nikkei pattern and why this might be your last chance to buy 8:28 a.m. Feb. 5, 2014 - blogs.marketwatch.com
Merck 4Q profit falls on weaker sales 8:21 a.m. Feb. 5, 2014 - MarketWatch.com
Merck fourth-quarter profit, revenue fall 7:14 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck sees 2014 adj. EPS of $3.35 to $3.53 7:05 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck Q4 sales fall to $11.32 bln from $11.74 bln 7:03 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck Q4 profit falls to $781 mln from $908 mln 7:03 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck Q4 EPS $0.26; Adj. EPS $0.88 7:03 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Time Warner, Twitter, Walt Disney are stocks to watch 5:48 a.m. Feb. 5, 2014 - Sue Chang
Utility stocks gain as Treasury yields lag 4:06 p.m. Feb. 4, 2014 - Wallace Witkowski
The market in a minute: Bull vs. bear margin thins 9:17 a.m. Feb. 3, 2014 - The Trading Deck
‘Par’ earnings not good enough after 2013 stock run-up 10:13 p.m. Jan. 31, 2014 - Wallace Witkowski
Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Saumya Vaishampayan
Technical damage inflicted, S&P’s trend turns lower 11:49 a.m. Jan. 27, 2014 - Michael Ashbaugh
Merck hits a new high as analyst sees opening for new cancer drug 11:16 a.m. Jan. 27, 2014 - blogs.marketwatch.com
How to Invest for Income 10:50 a.m. Today - Barrons.com
Stock Market News for February 19, 2014 - Market News 10:06 a.m. Today - Zacks.com
Buy Recommendation Reiterated For Merck & Co Inc 9:00 a.m. Today - TheStreet.com
Prana: Expect Success In Massive Binary Event 1:19 p.m. Feb. 18, 2014 - Seeking Alpha
7 Monthly Pay Valentine Dogs Stalk 17% To 32% Upsides 1:06 p.m. Feb. 18, 2014 - Seeking Alpha
Wall Street Winners: Were Analyst 2014 Picks Worth Their Salt? 8:53 a.m. Feb. 18, 2014 - Seeking Alpha
Biotech Buyout Bolsters Novartis Cancer Portfolio 6:19 a.m. Feb. 17, 2014 - 247WallSt.com
Johnson & Johnson: Nothing to Fix Here 6:00 a.m. Feb. 17, 2014 - TheStreet.com
Ligand Pharmaceuticals: 5 Different Insiders Have Sold Shares This Month 1:46 a.m. Feb. 17, 2014 - Seeking Alpha
Merck: 7 Different Insiders Have Sold Shares This Month 3:04 a.m. Feb. 16, 2014 - Seeking Alpha
Merck's Decision To Sell Consumer Division Is Timely And Will Lead To A Higher Stock Price 6:38 p.m. Feb. 14, 2014 - Seeking Alpha
Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender 11:56 a.m. Feb. 14, 2014 - Seeking Alpha
The 3 Best Vanguard Funds for an Uncertain Market 7:00 a.m. Feb. 14, 2014 - InvestorPlace.com
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer Needs a Healthy Dose of Investor Love 6:00 a.m. Feb. 14, 2014 - TheStreet.com
8 Pharmaceutical Stocks to Buy Now 2:15 a.m. Feb. 14, 2014 - InvestorPlace.com
Celsion's Newest Cancer Treatment Adds To Upside 4:37 p.m. Feb. 13, 2014 - Seeking Alpha
Pfizer's Finally a Buy 1:13 p.m. Feb. 13, 2014 - Barrons.com
Marginal Earnings Beat at Hospira in Q4 (Revised) - Analyst Blog 11:20 a.m. Feb. 13, 2014 - Zacks.com
Feb. 13 Premarket Briefing: 10 Things You Should Know 8:09 a.m. Feb. 13, 2014 - TheStreet.com
Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy 8:05 a.m. Feb. 18, 2014 - PR Newswire - PRF
Iroko Pharmaceuticals Makes Strategic Additions to the Company’s Board of Directors 8:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
John Daly, Worked With Merck, American Airlines, IBM and Is the White House Author of Advocacy 1:36 p.m. Feb. 17, 2014 - Marketwire
MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner) 3:00 a.m. Feb. 17, 2014 - BusinessWire - BZX
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities 4:00 p.m. Feb. 13, 2014 - BusinessWire - BZX
Sonrgy Announces Key Management Recruits 11:10 a.m. Feb. 13, 2014 - BusinessWire - BZX
Diabetes - KOL Insight and Consensus Outlook Modules 10:34 a.m. Feb. 13, 2014 - PR Newswire - PRF
Brazilian Pharmaceutical Market 2014-2024 10:03 a.m. Feb. 12, 2014 - PR Newswire - PRF
BIO-Europe Spring® Program in Turin Will Engage Executives in Provocative Topics Facing Drug Development Industry 9:00 a.m. Feb. 12, 2014 - BusinessWire - BZX
HTG Molecular Diagnostics Completes Initial Series E Preferred Stock Offering 7:02 a.m. Feb. 11, 2014 - Marketwire
Legal-Bay Lawsuit Settlement Funding Announce Settlements in Biomet Hip and NuvaRing Litigations 5:00 a.m. Feb. 11, 2014 - PR Newswire - PRF
Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes 8:30 a.m. Feb. 10, 2014 - BusinessWire - BZX
Absence of Blockbuster Drug Launches in 2014 Puts R&D Productivity at Risk 9:00 a.m. Feb. 5, 2014 - BusinessWire - BZX
Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results 7:00 a.m. Feb. 5, 2014 - BusinessWire - BZX
Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 6:40 a.m. Feb. 5, 2014 - BusinessWire - BZX
Amgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma 6:15 a.m. Feb. 5, 2014 - PR Newswire - PRF
EffRx signs distribution agreements for Binosto® in Italy, Spain and Portugal 9:13 a.m. Feb. 4, 2014 - BusinessWire - BZX
Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 8:30 a.m. Feb. 3, 2014 - BusinessWire - BZX
Updates, advisories and surprises 6:01 p.m. Feb. 5, 2014 - MarketWatch
U.S. stocks fall; data stoke fears of slowdown 4:31 p.m. Feb. 5, 2014 - Anora Mahmudova
Stocks dip, end off day's lows; Twitter falls after hours: stock market live blog recap 4:27 p.m. Feb. 5, 2014 - blogs.marketwatch.com
3D Systems down on weak outlook, CVS quits cigarettes 4:16 p.m. Feb. 5, 2014 - Saumya Vaishampayan
The big Merck news centers on cancer-drug collaborations with other giants 11:02 a.m. Feb. 5, 2014 - blogs.marketwatch.com
U.S. stock futures turn up before market open 9:21 a.m. Feb. 5, 2014 - Barbara Kollmeyer
Twitter, the Nikkei pattern and why this might be your last chance to buy 8:28 a.m. Feb. 5, 2014 - blogs.marketwatch.com
Merck 4Q profit falls on weaker sales 8:21 a.m. Feb. 5, 2014 - MarketWatch.com
Merck fourth-quarter profit, revenue fall 7:14 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck sees 2014 adj. EPS of $3.35 to $3.53 7:05 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck Q4 sales fall to $11.32 bln from $11.74 bln 7:03 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck Q4 profit falls to $781 mln from $908 mln 7:03 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Merck Q4 EPS $0.26; Adj. EPS $0.88 7:03 a.m. Feb. 5, 2014 - Saumya Vaishampayan
Time Warner, Twitter, Walt Disney are stocks to watch 5:48 a.m. Feb. 5, 2014 - Sue Chang
Utility stocks gain as Treasury yields lag 4:06 p.m. Feb. 4, 2014 - Wallace Witkowski
The market in a minute: Bull vs. bear margin thins 9:17 a.m. Feb. 3, 2014 - The Trading Deck
‘Par’ earnings not good enough after 2013 stock run-up 10:13 p.m. Jan. 31, 2014 - Wallace Witkowski
Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Saumya Vaishampayan
Technical damage inflicted, S&P’s trend turns lower 11:49 a.m. Jan. 27, 2014 - Michael Ashbaugh
Merck hits a new high as analyst sees opening for new cancer drug 11:16 a.m. Jan. 27, 2014 - blogs.marketwatch.com
How to Invest for Income 10:50 a.m. Today - Barrons.com
Stock Market News for February 19, 2014 - Market News 10:06 a.m. Today - Zacks.com
Buy Recommendation Reiterated For Merck & Co Inc 9:00 a.m. Today - TheStreet.com
Prana: Expect Success In Massive Binary Event 1:19 p.m. Feb. 18, 2014 - Seeking Alpha
7 Monthly Pay Valentine Dogs Stalk 17% To 32% Upsides 1:06 p.m. Feb. 18, 2014 - Seeking Alpha
Wall Street Winners: Were Analyst 2014 Picks Worth Their Salt? 8:53 a.m. Feb. 18, 2014 - Seeking Alpha
Biotech Buyout Bolsters Novartis Cancer Portfolio 6:19 a.m. Feb. 17, 2014 - 247WallSt.com
Johnson & Johnson: Nothing to Fix Here 6:00 a.m. Feb. 17, 2014 - TheStreet.com
Ligand Pharmaceuticals: 5 Different Insiders Have Sold Shares This Month 1:46 a.m. Feb. 17, 2014 - Seeking Alpha
Merck: 7 Different Insiders Have Sold Shares This Month 3:04 a.m. Feb. 16, 2014 - Seeking Alpha
Merck's Decision To Sell Consumer Division Is Timely And Will Lead To A Higher Stock Price 6:38 p.m. Feb. 14, 2014 - Seeking Alpha
Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender 11:56 a.m. Feb. 14, 2014 - Seeking Alpha
The 3 Best Vanguard Funds for an Uncertain Market 7:00 a.m. Feb. 14, 2014 - InvestorPlace.com
AbbVie Deserves More Respect 6:30 a.m. Feb. 14, 2014 - TheStreet.com
Pfizer Needs a Healthy Dose of Investor Love 6:00 a.m. Feb. 14, 2014 - TheStreet.com
8 Pharmaceutical Stocks to Buy Now 2:15 a.m. Feb. 14, 2014 - InvestorPlace.com
Celsion's Newest Cancer Treatment Adds To Upside 4:37 p.m. Feb. 13, 2014 - Seeking Alpha
Pfizer's Finally a Buy 1:13 p.m. Feb. 13, 2014 - Barrons.com
Marginal Earnings Beat at Hospira in Q4 (Revised) - Analyst Blog 11:20 a.m. Feb. 13, 2014 - Zacks.com
Feb. 13 Premarket Briefing: 10 Things You Should Know 8:09 a.m. Feb. 13, 2014 - TheStreet.com
Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of Inhalation Strategy 8:05 a.m. Feb. 18, 2014 - PR Newswire - PRF
Iroko Pharmaceuticals Makes Strategic Additions to the Company’s Board of Directors 8:00 a.m. Feb. 18, 2014 - BusinessWire - BZX
John Daly, Worked With Merck, American Airlines, IBM and Is the White House Author of Advocacy 1:36 p.m. Feb. 17, 2014 - Marketwire
MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner) 3:00 a.m. Feb. 17, 2014 - BusinessWire - BZX
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities 4:00 p.m. Feb. 13, 2014 - BusinessWire - BZX
Sonrgy Announces Key Management Recruits 11:10 a.m. Feb. 13, 2014 - BusinessWire - BZX
Diabetes - KOL Insight and Consensus Outlook Modules 10:34 a.m. Feb. 13, 2014 - PR Newswire - PRF
Brazilian Pharmaceutical Market 2014-2024 10:03 a.m. Feb. 12, 2014 - PR Newswire - PRF
BIO-Europe Spring® Program in Turin Will Engage Executives in Provocative Topics Facing Drug Development Industry 9:00 a.m. Feb. 12, 2014 - BusinessWire - BZX
HTG Molecular Diagnostics Completes Initial Series E Preferred Stock Offering 7:02 a.m. Feb. 11, 2014 - Marketwire
Legal-Bay Lawsuit Settlement Funding Announce Settlements in Biomet Hip and NuvaRing Litigations 5:00 a.m. Feb. 11, 2014 - PR Newswire - PRF
Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes 8:30 a.m. Feb. 10, 2014 - BusinessWire - BZX
Absence of Blockbuster Drug Launches in 2014 Puts R&D Productivity at Risk 9:00 a.m. Feb. 5, 2014 - BusinessWire - BZX
Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results 7:00 a.m. Feb. 5, 2014 - BusinessWire - BZX
Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies 6:45 a.m. Feb. 5, 2014 - BusinessWire - BZX
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475 6:40 a.m. Feb. 5, 2014 - BusinessWire - BZX
Amgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma 6:15 a.m. Feb. 5, 2014 - PR Newswire - PRF
EffRx signs distribution agreements for Binosto® in Italy, Spain and Portugal 9:13 a.m. Feb. 4, 2014 - BusinessWire - BZX
Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 8:30 a.m. Feb. 3, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼
